The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Authors:
Open Access
- 19 August 2014
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 2 (1) , 29
Abstract
Antibodies targeting T-cell inhibitory pathways, such as CTLA-4 and PD-1/PD-L1, are emerging as an important class of cancer therapeutics, and a next generation of immunomodulatory therapies targeting alternative inhibitory (e.g. TIM-3, LAG-3, B7-H4, B7-H3, VISTA, A2aR), as well as co-stimulatory (e.g. CD27, OX40, GITR, CD137), pathways are poised to join them. Most of these immunomodulatory antibodies are of IgG isotypes that have low, or no, binding to the Fc gamma receptors (FcγRs) that trigger cell-mediated cytotoxic effector functions such as antibody dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). These isotypes were selected to minimise the risk of depleting the T cells upon which such antibodies depend for their mechanism of action. However, recent preclinical data highlight a potential role for FcγR engagement in the activity of such antibodies. Here we review the biology of the FcγRs and IgG isotypes in both humans and mice, detail the potential roles that FcγR interactions can play in the activity of monoclonal antibodies in general, and of immunomodulatory antibodies in particular, and discuss how preclinical studies on these interactions might be best interpreted and translated to a human setting.Keywords
This publication has 44 references indexed in Scilit:
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerJournal of Hematology & Oncology, 2013
- CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1‐inducing role of mesenteric lymph node macrophages during colitisEuropean Journal of Immunology, 2012
- Properties of mouse and human IgG receptors and their contribution to disease modelsBlood, 2012
- Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclassesBlood, 2009
- Fcγ receptors as regulators of immune responsesNature Reviews Immunology, 2008
- Engineered antibody Fc variants with enhanced effector functionProceedings of the National Academy of Sciences, 2006
- FcγRIV: A Novel FcR with Distinct IgG Subclass SpecificityImmunity, 2005
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNature Medicine, 2000